Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9UK41

UPID:
VPS28_HUMAN

ALTERNATIVE NAMES:
ESCRT-I complex subunit VPS28

ALTERNATIVE UPACC:
Q9UK41; Q86VK0

BACKGROUND:
The ESCRT-I complex subunit VPS28, also known as Vacuolar protein sorting-associated protein 28 homolog, is integral to the endosomal sorting complex required for transport. This protein facilitates the sorting and degradation of ubiquitinated proteins, playing a vital role in endocytic trafficking and the prevention of cellular toxicity. VPS28's function is essential for the maintenance of cellular integrity and the proper execution of vesicular trafficking processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of ESCRT-I complex subunit VPS28 offers a promising avenue for the development of novel therapeutic interventions. Given its central role in the regulation of protein sorting and degradation, targeting VPS28 could provide innovative treatments for conditions characterized by abnormal protein accumulation or trafficking.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.